A complete guide to using acalatinib and patient medication guide sharing

Acalabrutinib, also known as acalabrutinib, is a new generation of Bruton's tyrosine kinase (BTK) inhibitor, mainly used to treat chronic lymphocytic leukemia (BTK pan>CLL), mantle cell lymphoma (MCL) and other B cell-related malignant tumors. As an important representative drug of targeted therapy, acotinib has attracted much attention from patients and doctors in recent years due to its strong selectivity, few side effects, and remarkable efficacy. This article will introduce in detail the complete guide to the use of acotinib and patient medication guidelines to help patients better understand and rationally use the drug.

1. Mechanism of action and indications of acotinib

Acotinib achieves anti-cancer effects by specifically inhibiting the BTK signaling pathway, blocking the signal transduction mediated by the B cell receptor (BCR), and inhibiting the proliferation and survival of malignant B cells. Compared with the first-generation BTK inhibitor ibrutinib, acotinib is more selective for BTK, reduces the inhibition of other kinases, and reduces some adverse reactions, especially arrhythmia and bleeding risk.

Acotinib is mainly suitable for the treatment of patients with relapsed /refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). In 2020China's State Food and Drug Administration approved acotinib for marketing, becoming one of the first BTK inhibitors in China, providing a new treatment option for patients with B cell malignant tumors. In addition, acotinib has shown good efficacy and safety in multiple clinical trials and has been gradually included in multinational treatment guidelines.

2. Medication dosage and administration method

Acotinib is generally administered orally, and the recommended dose is 100mg twice a day (once in the morning and once in the evening), and can be taken on an empty stomach or after a meal. Patients should strictly follow the doctor's prescription and instructions for taking the medicine, and are not allowed to adjust the dosage or frequency on their own. If you miss a dose, you should take it as soon as possible. However, if it is close to the next dose time, skip this dose to avoid overdose.

It is recommended to take the medicine with enough water and avoid chewing or crushing the tablets. If the patient has difficulty swallowing, appropriate auxiliary measures can be taken under the guidance of a doctor. Regular blood routine, liver and kidney function and electrocardiogram monitoring are performed to promptly evaluate the safety and efficacy of medication. Also, your doctor should be informed of all medications you are taking to avoid potential drug interactions.

3. Common side effects and countermeasures

Acotinib is generally well tolerated, but some patients may experience adverse reactions such as headache, fatigue, diarrhea, nausea, nose bleeding, or thrombocytopenia. Headaches are relatively common, mostly mild to moderate, and generally require no special treatment. Just rest. If severe diarrhea or persistent vomiting occurs, seek medical attention promptly to avoid dehydration or electrolyte imbalance.

In terms of heart, acotinib has a lower risk of arrhythmia than ibrutinib, but symptoms of palpitations or chest tightness still need to be paid attention to. Patients should undergo regular electrocardiogram examinations during medication, and treatment should be adjusted in a timely manner if abnormalities are found. If severe bleeding or coagulation abnormalities occur, you should contact your doctor immediately. Medication may need to be adjusted or discontinued.

4. Medication precautions and life suggestions

Patients should avoid concurrent use of anticoagulants or NSAIDs drugs while taking acotinib to reduce the risk of bleeding. Pregnant and lactating women are prohibited from using this medicine. If you plan to become pregnant or breast-feeding, inform your doctor.

In addition, patients should maintain good living habits, eat reasonably, exercise moderately, and enhance body immunity. Avoid strenuous exercise and trauma to prevent bleeding. Regularly review blood indicators and tumor conditions, provide timely feedback on physical conditions, and ensure that the treatment plan is scientific and reasonable.

In short, acotinib, as a new generation of BTK inhibitor, has shown good efficacy and safety in the field of B cell tumor treatment. Patients should strictly abide by the doctor's instructions, pay attention to drug side effects, make reasonable lifestyle adjustments, and actively cooperate with clinical follow-up. Through scientific and standardized medication management, the therapeutic advantages of acotinib can be maximized and patients' quality of life and survival expectations can be improved.

Reference: https://go.drugbank.com/drugs/

xa0